Teratology Society Joins Patients Alliance to Preserve REMS

Teratology Society Joins Patients Alliance to Preserve REMS

Washington, DC - The Teratology Society, the premier source for cutting-edge research and authoritative information related to birth defects and developmentally-mediated disorders, announces its participation in the Patients Alliance for Drug Safety Protections, a new coalition aimed at educating the public about the importance of Risk Evaluation and Mitigation Strategies (REMS).

“The Teratology Society is dedicated to the research and prevention of birth defects.  The FDA REMS system is a crucial mechanism to allow patients to obtain high risk treatments for serious diseases, while protecting them from the serious side effects associated with these therapies, including birth defects,” said Tacey E.K. White, PhD, Teratology Society president. “The Teratology Society applauds the efforts of the Patient Safety Alliance to ensure that REMS programs are upheld and that all originator and generic drug manufacturers follow appropriate ETASU when conducting studies with these drugs in order to protect patients and their babies.”

The Alliance consists of public health, as well as health professionals and diseases organizations, including the American Cancer Society Action Network, American College of Obstetricians and Gynecologists, March of Dimes and MotherToBaby, a service of the Organization of Teratology Information Specialists, among others.

To read more about the new Alliance and all of the organizations involved, please read the press release announcement here.

 

Recent Stories
Announcing the New Teratology Society Innovator Award

FDA Launches Predictive Toxicology Roadmap

PODCAST: Secrets of the Human Brain Revealed: Development, Disease & the Zika Virus